1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A456E16FD3D7A248852575F4004258E2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-leveraging-health-outcomes-research-to-drive-sales?opendocument
18
19opendocument
2035.172.195.49
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Leveraging Health Outcomes Research to Drive Sales

ID: 5043


Features:

10 Info Graphics

28 Data Graphics

170+ Metrics

9 Narratives

5 Best Practices


Pages/Slides: 48


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
Optimizing the utilization of Health Outcomes data has become increasingly important to the success of biotechnology and pharmaceutical companies. This study aims to discover and collect best practices in how companies use and review the use of Health Outcomes data internally and across different functional areas. The study provides comparative data from 2009 and 2011. Executives and managers involved in the utilization of Health Outcomes data can use this study to compare their procedures and tactics with leading organizations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Manufacturing; Biotech; Consumer Products; Consulting


Companies Profiled:
Abbott; Alfred Mann Foundation; ASSESSmint; Baxter; Bayer; Becton Dickinson; C. Kalb & Associates; LLC; Eisai Inc; Laboratorios Esteve; Mahde Taban; Medtronic; Novo Nordisk A/S; Pfizer; Regeneron Pharmaceuticals; Shire

Study Snapshot

This research is based on comparative benchmark survey data from 2009 and 2011. The 2011 benchmark class includes 18 participants from 16 companies across pharmaceutical, biotechnology and device industries; the 2009 data is based on insights from 33 participants from 29 pharmaceutical, biotech and medical device companies.

Key topics include:

  • Health outcomes reporting structuring
  • Utilizing health outcomes data
  • Health outcomes data review process
  • Health outcomes data overview
  • Health outcome data best practices insights

Sample Key Findings

Health Outcomes Sits Within a Centralized Organization: No structure is perfect, but two-thirds of companies place their Health Outcomes Group as part of a centralized organization.
  • Health Outcomes Remains Conservative on its Review Approach: All companies tend to have their Health Outcomes data reviewed by groups that include Medical Affairs, Legal and Regulatory, with some input from the Commercial/Marketing groups. For the most part, companies remain consistent in their approach to reviewing data that could be used for promotional purposes.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.